Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, reflecting increased provider awareness and adoption,” said Bill Duke, Chief Financial Officer of Invivyd (IVVD). “We look forward to raising further awareness of PEMGARDA in the healthcare community and working to achieve near-term profitability. In parallel, we are advancing VYD2311, our next generation monoclonal antibody that has demonstrated highly promising Phase 1 clinical data and has the potential to offer an improved route of administration to protect vulnerable patient populations from COVID-19.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd announces in vitro neutralization data for PEMGARDA
- Biotech Alert: Searches spiking for these stocks today
- Invivyd news ‘disappointing’ but not in model, says H.C. Wainwright
- Invivyd’s Strategic Positioning and Growth Potential in COVID-19 Prophylaxis Market: A Buy Rating Despite Regulatory Challenges
- Invivyd says FDA declines request to expand existing EUA of PEMGARDA
Questions or Comments about the article? Write to editor@tipranks.com